ALADDIN project
@projectaladdin.bsky.social
ALADDIN is an #EICPathfinder 🇪🇺 project accelerating the discovery of therapeutic nanobodies for improved treatment of cancer. 🔗: https://aladdin-project.eu/
Today is World Pancreatic Cancer Day, a day all about raising awareness of the risks and symptoms of this cancer.
In ALADDIN, we study pancreatic cancer patients’ samples to identify therapeutic targets, contributing to the work towards improved treatments for cancer.
#WPCD
In ALADDIN, we study pancreatic cancer patients’ samples to identify therapeutic targets, contributing to the work towards improved treatments for cancer.
#WPCD
November 20, 2025 at 8:30 AM
Today is World Pancreatic Cancer Day, a day all about raising awareness of the risks and symptoms of this cancer.
In ALADDIN, we study pancreatic cancer patients’ samples to identify therapeutic targets, contributing to the work towards improved treatments for cancer.
#WPCD
In ALADDIN, we study pancreatic cancer patients’ samples to identify therapeutic targets, contributing to the work towards improved treatments for cancer.
#WPCD
Uncovering dormancy in colorectal cancer 🧬
Colorectal cancer remains one of the most prevalent and deadly cancers worldwide, with up to 50% of patients relapsing after treatment.
This study explores tumour dormancy and biomarkers to predict recurrence.
pubmed.ncbi.nlm.nih....
Colorectal cancer remains one of the most prevalent and deadly cancers worldwide, with up to 50% of patients relapsing after treatment.
This study explores tumour dormancy and biomarkers to predict recurrence.
pubmed.ncbi.nlm.nih....
November 18, 2025 at 12:00 PM
Uncovering dormancy in colorectal cancer 🧬
Colorectal cancer remains one of the most prevalent and deadly cancers worldwide, with up to 50% of patients relapsing after treatment.
This study explores tumour dormancy and biomarkers to predict recurrence.
pubmed.ncbi.nlm.nih....
Colorectal cancer remains one of the most prevalent and deadly cancers worldwide, with up to 50% of patients relapsing after treatment.
This study explores tumour dormancy and biomarkers to predict recurrence.
pubmed.ncbi.nlm.nih....
ALADDIN in the spotlight 💡
Researcher Lidia Cerdán García recently presented our project at the "V Jornadas Científicas PTI+ Salud Global" event in Madrid, Spain.
The event focused on the research conducted at our coordinating institution, the Spanish National Research Council @csic.es!
Researcher Lidia Cerdán García recently presented our project at the "V Jornadas Científicas PTI+ Salud Global" event in Madrid, Spain.
The event focused on the research conducted at our coordinating institution, the Spanish National Research Council @csic.es!
November 18, 2025 at 7:30 AM
ALADDIN in the spotlight 💡
Researcher Lidia Cerdán García recently presented our project at the "V Jornadas Científicas PTI+ Salud Global" event in Madrid, Spain.
The event focused on the research conducted at our coordinating institution, the Spanish National Research Council @csic.es!
Researcher Lidia Cerdán García recently presented our project at the "V Jornadas Científicas PTI+ Salud Global" event in Madrid, Spain.
The event focused on the research conducted at our coordinating institution, the Spanish National Research Council @csic.es!
In ALADDIN, synthetic biology works hand in hand with #AI!
Using AI, structural predictions can be done to...
💻 Model how nanobodies bind to antigens
💻 Optimise and humanise nanobodies
AI modelling in the project is done by @hebrewuniversity.bsky.social
#ALADDINproject #EICPathfinder
Using AI, structural predictions can be done to...
💻 Model how nanobodies bind to antigens
💻 Optimise and humanise nanobodies
AI modelling in the project is done by @hebrewuniversity.bsky.social
#ALADDINproject #EICPathfinder
November 16, 2025 at 9:00 AM
In ALADDIN, synthetic biology works hand in hand with #AI!
Using AI, structural predictions can be done to...
💻 Model how nanobodies bind to antigens
💻 Optimise and humanise nanobodies
AI modelling in the project is done by @hebrewuniversity.bsky.social
#ALADDINproject #EICPathfinder
Using AI, structural predictions can be done to...
💻 Model how nanobodies bind to antigens
💻 Optimise and humanise nanobodies
AI modelling in the project is done by @hebrewuniversity.bsky.social
#ALADDINproject #EICPathfinder
Microfluidics form a crucial ingredient in our project approach ✅
In ALADDIN, the @inlnano.bsky.social team...
🔬Develops microfluidics devices to select nanobodies from bacteria
🔬Implement the devices into the multidisciplinary ALADDIN platform
#ALADDINproject #EICPathfinder
In ALADDIN, the @inlnano.bsky.social team...
🔬Develops microfluidics devices to select nanobodies from bacteria
🔬Implement the devices into the multidisciplinary ALADDIN platform
#ALADDINproject #EICPathfinder
November 12, 2025 at 8:39 AM
Microfluidics form a crucial ingredient in our project approach ✅
In ALADDIN, the @inlnano.bsky.social team...
🔬Develops microfluidics devices to select nanobodies from bacteria
🔬Implement the devices into the multidisciplinary ALADDIN platform
#ALADDINproject #EICPathfinder
In ALADDIN, the @inlnano.bsky.social team...
🔬Develops microfluidics devices to select nanobodies from bacteria
🔬Implement the devices into the multidisciplinary ALADDIN platform
#ALADDINproject #EICPathfinder
Mathematical modelling is a key part of the ALADDIN project 📈
It’s crucial for:
🔎 The identification of therapeutic targets
🔎 The preclinical validation of nanobodies in zebrafish
The power of mathematics is unleashed in our project by InCELLia!
#ALADDINproject #EICPathfinder
It’s crucial for:
🔎 The identification of therapeutic targets
🔎 The preclinical validation of nanobodies in zebrafish
The power of mathematics is unleashed in our project by InCELLia!
#ALADDINproject #EICPathfinder
November 10, 2025 at 6:30 AM
Mathematical modelling is a key part of the ALADDIN project 📈
It’s crucial for:
🔎 The identification of therapeutic targets
🔎 The preclinical validation of nanobodies in zebrafish
The power of mathematics is unleashed in our project by InCELLia!
#ALADDINproject #EICPathfinder
It’s crucial for:
🔎 The identification of therapeutic targets
🔎 The preclinical validation of nanobodies in zebrafish
The power of mathematics is unleashed in our project by InCELLia!
#ALADDINproject #EICPathfinder
Refining prognosis in pancreatic cancer 🎯
Accurate staging is vital for improving outcomes in pancreatic adenocarcinoma.
A study comparing the 7th and 8th editions of the AJCC TNM staging system in 214 surgically treated patients reveals key findings.
pubmed.ncbi.nlm.nih....
Accurate staging is vital for improving outcomes in pancreatic adenocarcinoma.
A study comparing the 7th and 8th editions of the AJCC TNM staging system in 214 surgically treated patients reveals key findings.
pubmed.ncbi.nlm.nih....
November 6, 2025 at 10:30 AM
Refining prognosis in pancreatic cancer 🎯
Accurate staging is vital for improving outcomes in pancreatic adenocarcinoma.
A study comparing the 7th and 8th editions of the AJCC TNM staging system in 214 surgically treated patients reveals key findings.
pubmed.ncbi.nlm.nih....
Accurate staging is vital for improving outcomes in pancreatic adenocarcinoma.
A study comparing the 7th and 8th editions of the AJCC TNM staging system in 214 surgically treated patients reveals key findings.
pubmed.ncbi.nlm.nih....
Did you know?
By combining omics, mathematical models, synthetic biology, AI & microfluidics, we can...
🔎 Identify novel therapeutic targets
💡 Predict which nanobodies will bind best to their targets
🙌 Validate the efficacy of the nanobodies
aladdin-project.eu/a...
By combining omics, mathematical models, synthetic biology, AI & microfluidics, we can...
🔎 Identify novel therapeutic targets
💡 Predict which nanobodies will bind best to their targets
🙌 Validate the efficacy of the nanobodies
aladdin-project.eu/a...
October 31, 2025 at 12:47 PM
Did you know?
By combining omics, mathematical models, synthetic biology, AI & microfluidics, we can...
🔎 Identify novel therapeutic targets
💡 Predict which nanobodies will bind best to their targets
🙌 Validate the efficacy of the nanobodies
aladdin-project.eu/a...
By combining omics, mathematical models, synthetic biology, AI & microfluidics, we can...
🔎 Identify novel therapeutic targets
💡 Predict which nanobodies will bind best to their targets
🙌 Validate the efficacy of the nanobodies
aladdin-project.eu/a...
ALADDIN at the XXI National Meeting of Sociedad Española de Biología Celular 🙌
Last week, PI Javier Martinez-Useros from the Instituto Investigación Sanitaria Fundación Jiménez Díaz joined the event and presented the ALADDIN project.
#ALADDINproject #EICPathfinder
Last week, PI Javier Martinez-Useros from the Instituto Investigación Sanitaria Fundación Jiménez Díaz joined the event and presented the ALADDIN project.
#ALADDINproject #EICPathfinder
October 31, 2025 at 12:23 PM
ALADDIN at the XXI National Meeting of Sociedad Española de Biología Celular 🙌
Last week, PI Javier Martinez-Useros from the Instituto Investigación Sanitaria Fundación Jiménez Díaz joined the event and presented the ALADDIN project.
#ALADDINproject #EICPathfinder
Last week, PI Javier Martinez-Useros from the Instituto Investigación Sanitaria Fundación Jiménez Díaz joined the event and presented the ALADDIN project.
#ALADDINproject #EICPathfinder
50 years on: monoclonal antibodies evolved from lab reagents to lifesaving drugs for millions. 🎉
This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design.
Read more:
This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design.
Read more:
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Nature Reviews Immunology - Fifty years ago, Köhler and Milstein introduced the world to hybridoma technology for the generation of monoclonal antibodies. Scientists have subsequently built...
www.nature.com
October 29, 2025 at 9:08 AM
50 years on: monoclonal antibodies evolved from lab reagents to lifesaving drugs for millions. 🎉
This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design.
Read more:
This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design.
Read more:
Stay up to date on the latest ALADDIN news! 📰
Our blog is the go-to for relevant updates about the project. Discover our meeting summaries, interviews with project partners, and more:
aladdin-project.eu/n...
Our blog is the go-to for relevant updates about the project. Discover our meeting summaries, interviews with project partners, and more:
aladdin-project.eu/n...
October 23, 2025 at 12:00 PM
Stay up to date on the latest ALADDIN news! 📰
Our blog is the go-to for relevant updates about the project. Discover our meeting summaries, interviews with project partners, and more:
aladdin-project.eu/n...
Our blog is the go-to for relevant updates about the project. Discover our meeting summaries, interviews with project partners, and more:
aladdin-project.eu/n...
Pancreatic cancer is deadly & early detection is difficult.
Blood-circulating miRNAs show promise as minimally invasive biomarkers for early diagnosis, as shown in this review by Powrózek et al.🩸
Discover the latest findings:
Blood-circulating miRNAs show promise as minimally invasive biomarkers for early diagnosis, as shown in this review by Powrózek et al.🩸
Discover the latest findings:
Blood circulating miRNAs as pancreatic cancer biomarkers: An evidence from pooled analysis and bioinformatics study
Pancreatic cancer (PC) is one of the deadliest cancers, characterized by a poor prognosis. Currently, there are no screening programs for the early de…
www.sciencedirect.com
October 21, 2025 at 8:30 AM
Pancreatic cancer is deadly & early detection is difficult.
Blood-circulating miRNAs show promise as minimally invasive biomarkers for early diagnosis, as shown in this review by Powrózek et al.🩸
Discover the latest findings:
Blood-circulating miRNAs show promise as minimally invasive biomarkers for early diagnosis, as shown in this review by Powrózek et al.🩸
Discover the latest findings:
Collaboration fueling innovation 🤝🔬
At ALADDIN, partners across Europe are working together to accelerate nanobody discovery and validate their effectiveness against pancreatic and colorectal cancers.
🔗: aladdin-project.eu/c...
At ALADDIN, partners across Europe are working together to accelerate nanobody discovery and validate their effectiveness against pancreatic and colorectal cancers.
🔗: aladdin-project.eu/c...
October 16, 2025 at 6:15 AM
Collaboration fueling innovation 🤝🔬
At ALADDIN, partners across Europe are working together to accelerate nanobody discovery and validate their effectiveness against pancreatic and colorectal cancers.
🔗: aladdin-project.eu/c...
At ALADDIN, partners across Europe are working together to accelerate nanobody discovery and validate their effectiveness against pancreatic and colorectal cancers.
🔗: aladdin-project.eu/c...
Last month, the ALADDIN team at @inlnano.bsky.social presented the project during an Early-Stage Researcher career fair. 🧬
During the event, which also attracted visitors from R&I-based companies, Alejandro Rodriguez & Mohammad Kiani presented the microfluidics devices developed in ALADDIN. 🔬
During the event, which also attracted visitors from R&I-based companies, Alejandro Rodriguez & Mohammad Kiani presented the microfluidics devices developed in ALADDIN. 🔬
October 14, 2025 at 6:30 AM
Last month, the ALADDIN team at @inlnano.bsky.social presented the project during an Early-Stage Researcher career fair. 🧬
During the event, which also attracted visitors from R&I-based companies, Alejandro Rodriguez & Mohammad Kiani presented the microfluidics devices developed in ALADDIN. 🔬
During the event, which also attracted visitors from R&I-based companies, Alejandro Rodriguez & Mohammad Kiani presented the microfluidics devices developed in ALADDIN. 🔬
50 years on: monoclonal antibodies evolved from lab reagents to lifesaving drugs for millions. 🎉
This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design.
Read more:
This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design.
Read more:
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Nature Reviews Immunology - Fifty years ago, Köhler and Milstein introduced the world to hybridoma technology for the generation of monoclonal antibodies. Scientists have subsequently built...
www.nature.com
October 13, 2025 at 8:00 AM
50 years on: monoclonal antibodies evolved from lab reagents to lifesaving drugs for millions. 🎉
This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design.
Read more:
This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design.
Read more:
Recap of our second annual meeting 🔔
Last month, the ALADDIN consortium came together in Linköping, Sweden, to exchange news on project progress and future plans.
Read the summary of the meeting in our blog: aladdin-project.eu/aladdin-seco...
Last month, the ALADDIN consortium came together in Linköping, Sweden, to exchange news on project progress and future plans.
Read the summary of the meeting in our blog: aladdin-project.eu/aladdin-seco...
ALADDIN hosts second annual meeting in Linköping, Sweden – aladdin-project.eu
aladdin-project.eu
October 12, 2025 at 9:35 AM
Recap of our second annual meeting 🔔
Last month, the ALADDIN consortium came together in Linköping, Sweden, to exchange news on project progress and future plans.
Read the summary of the meeting in our blog: aladdin-project.eu/aladdin-seco...
Last month, the ALADDIN consortium came together in Linköping, Sweden, to exchange news on project progress and future plans.
Read the summary of the meeting in our blog: aladdin-project.eu/aladdin-seco...
Nanobodies are transforming modern medicine, but the path to discovery is long and costly.
ALADDIN accelerates nanobody discovery by integrating many technologies into one platform—from biological processes to AI, mathematical modelling & microfluidics tools💡
aladdin-project.eu/a...
ALADDIN accelerates nanobody discovery by integrating many technologies into one platform—from biological processes to AI, mathematical modelling & microfluidics tools💡
aladdin-project.eu/a...
October 9, 2025 at 1:00 PM
Nanobodies are transforming modern medicine, but the path to discovery is long and costly.
ALADDIN accelerates nanobody discovery by integrating many technologies into one platform—from biological processes to AI, mathematical modelling & microfluidics tools💡
aladdin-project.eu/a...
ALADDIN accelerates nanobody discovery by integrating many technologies into one platform—from biological processes to AI, mathematical modelling & microfluidics tools💡
aladdin-project.eu/a...
ALADDIN was represented at the Single Antidomain Antibodies Conference 2025 in Utrecht. 🇳🇱
Project researchers Lidia Cerdán & Yago Margolles presented posters & the ALADDIN coordinator, Luis Ángel Fernández, gave a presentation at the three-day event.
#ALADDINproject #singledomainantibodies
Project researchers Lidia Cerdán & Yago Margolles presented posters & the ALADDIN coordinator, Luis Ángel Fernández, gave a presentation at the three-day event.
#ALADDINproject #singledomainantibodies
October 8, 2025 at 4:42 PM
ALADDIN was represented at the Single Antidomain Antibodies Conference 2025 in Utrecht. 🇳🇱
Project researchers Lidia Cerdán & Yago Margolles presented posters & the ALADDIN coordinator, Luis Ángel Fernández, gave a presentation at the three-day event.
#ALADDINproject #singledomainantibodies
Project researchers Lidia Cerdán & Yago Margolles presented posters & the ALADDIN coordinator, Luis Ángel Fernández, gave a presentation at the three-day event.
#ALADDINproject #singledomainantibodies
50 years ago, a simple idea changed medicine forever 🧬
Discover how the invention of monoclonal antibodies revolutionised science and health care, and why free exchange of ideas was key to this breakthrough.
🔗 Read the story:
Discover how the invention of monoclonal antibodies revolutionised science and health care, and why free exchange of ideas was key to this breakthrough.
🔗 Read the story:
Monoclonal antibodies revolutionized biomedical science and health care
Nature - The story of the discovery of these molecules 50 years ago shows how the free exchange of ideas can lead to life-changing treatments.
www.nature.com
October 7, 2025 at 7:30 AM
50 years ago, a simple idea changed medicine forever 🧬
Discover how the invention of monoclonal antibodies revolutionised science and health care, and why free exchange of ideas was key to this breakthrough.
🔗 Read the story:
Discover how the invention of monoclonal antibodies revolutionised science and health care, and why free exchange of ideas was key to this breakthrough.
🔗 Read the story:
Replicating the human immune system to speed up therapeutic antibody discovery 🔬
ALADDIN develops a platform that brings various technologies together to rethink nanobody discovery.
In the long run, it can contribute to faster, more efficient drug development!
aladdin-project.eu/
ALADDIN develops a platform that brings various technologies together to rethink nanobody discovery.
In the long run, it can contribute to faster, more efficient drug development!
aladdin-project.eu/
September 30, 2025 at 1:00 PM
Replicating the human immune system to speed up therapeutic antibody discovery 🔬
ALADDIN develops a platform that brings various technologies together to rethink nanobody discovery.
In the long run, it can contribute to faster, more efficient drug development!
aladdin-project.eu/
ALADDIN develops a platform that brings various technologies together to rethink nanobody discovery.
In the long run, it can contribute to faster, more efficient drug development!
aladdin-project.eu/
Zebrafish at the forefront of cancer research 🐠
In ALADDIN, cancer tumours are transplanted into zebrafish embryos to study nanobody performance.
In our blog, Lasse Jensen from @liu.se explains why zebrafish are used in ALADDIN & his team’s role in the project.
aladdin-project.eu/l...
In ALADDIN, cancer tumours are transplanted into zebrafish embryos to study nanobody performance.
In our blog, Lasse Jensen from @liu.se explains why zebrafish are used in ALADDIN & his team’s role in the project.
aladdin-project.eu/l...
September 26, 2025 at 8:15 AM
Zebrafish at the forefront of cancer research 🐠
In ALADDIN, cancer tumours are transplanted into zebrafish embryos to study nanobody performance.
In our blog, Lasse Jensen from @liu.se explains why zebrafish are used in ALADDIN & his team’s role in the project.
aladdin-project.eu/l...
In ALADDIN, cancer tumours are transplanted into zebrafish embryos to study nanobody performance.
In our blog, Lasse Jensen from @liu.se explains why zebrafish are used in ALADDIN & his team’s role in the project.
aladdin-project.eu/l...
Can nanobodies be used to treat brain disorders?
There’s promise, as shown by a study by Mathieu Oosterlaken et al. published in @nature.com.
Researchers developed a bivalent nanobody that improved cognitive deficits in mice with NMDA receptor hypofunction. 🐁🧠
There’s promise, as shown by a study by Mathieu Oosterlaken et al. published in @nature.com.
Researchers developed a bivalent nanobody that improved cognitive deficits in mice with NMDA receptor hypofunction. 🐁🧠
Nanobody therapy rescues behavioural deficits of NMDA receptor hypofunction | Nature
There is an urgent need for efficient and innovative therapies to treat brain disorders such as psychiatric and neurodegenerative diseases. Immunotherapies have proved to be efficient in many medical areas, but have not been considered to treat brain diseases due to the poor brain penetration of immunoglobulins1,2. Here we developed a bivalent biparatopic antibody, made of two camelid heavy-chain antibodies (called nanobodies)3, one binding to, and the other potentiating the activity of, homodimeric metabotropic glutamate receptor 2. We show that this bivalent nanobody, given peripherally, reaches the brain and corrects cognitive deficits in two preclinical mouse models with endophenotypes resulting from NMDA receptor hypofunction. Notably, these in vivo effects last for at least 7 days after a single intraperitoneal injection and are maintained after subchronic treatment. Our results establish a proof of concept that nanobodies can target brain receptors, and pave the way for nanobody-based therapeutic strategies for the treatment of brain disorders. A bivalent biparatopic nanobody penetrates the brain, binds to and potentiates the activity of homodimeric metabotropic glutamate receptor 2, correcting cognitive deficits in two preclinical mouse models with endophenotypes resulting from NMDA receptor hypofunction.
www.nature.com
September 24, 2025 at 9:00 AM
Can nanobodies be used to treat brain disorders?
There’s promise, as shown by a study by Mathieu Oosterlaken et al. published in @nature.com.
Researchers developed a bivalent nanobody that improved cognitive deficits in mice with NMDA receptor hypofunction. 🐁🧠
There’s promise, as shown by a study by Mathieu Oosterlaken et al. published in @nature.com.
Researchers developed a bivalent nanobody that improved cognitive deficits in mice with NMDA receptor hypofunction. 🐁🧠
Nanobodies: tiny but powerful fragments of antibodies first discovered in camelids. 🐪
In ALADDIN, we’re developing a platform to enhance their discovery and engineering—supported by molecular biology, AI, mathematical modelling, and microfluidics. 🧬
aladdin-project.eu/
In ALADDIN, we’re developing a platform to enhance their discovery and engineering—supported by molecular biology, AI, mathematical modelling, and microfluidics. 🧬
aladdin-project.eu/
September 18, 2025 at 6:00 AM
Nanobodies: tiny but powerful fragments of antibodies first discovered in camelids. 🐪
In ALADDIN, we’re developing a platform to enhance their discovery and engineering—supported by molecular biology, AI, mathematical modelling, and microfluidics. 🧬
aladdin-project.eu/
In ALADDIN, we’re developing a platform to enhance their discovery and engineering—supported by molecular biology, AI, mathematical modelling, and microfluidics. 🧬
aladdin-project.eu/
Second annual meeting: completed 🚀
Earlier this month, the ALADDIN consortium came together in Sweden to discuss project progress and upcoming tasks.
Take a look at our blog for a recap of the meeting: aladdin-project.eu/aladdin-seco...
Earlier this month, the ALADDIN consortium came together in Sweden to discuss project progress and upcoming tasks.
Take a look at our blog for a recap of the meeting: aladdin-project.eu/aladdin-seco...
ALADDIN hosts second annual meeting in Linköping, Sweden – aladdin-project.eu
aladdin-project.eu
September 16, 2025 at 7:38 AM
Second annual meeting: completed 🚀
Earlier this month, the ALADDIN consortium came together in Sweden to discuss project progress and upcoming tasks.
Take a look at our blog for a recap of the meeting: aladdin-project.eu/aladdin-seco...
Earlier this month, the ALADDIN consortium came together in Sweden to discuss project progress and upcoming tasks.
Take a look at our blog for a recap of the meeting: aladdin-project.eu/aladdin-seco...
Nanobodies targeting lung cancer 🫁
Researchers at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) have developed a nanobody-based technology that identifies and attacks lung cancer cells, opening up new possibilities for cancer therapy.
Researchers at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) have developed a nanobody-based technology that identifies and attacks lung cancer cells, opening up new possibilities for cancer therapy.
Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery
Signal Transduction and Targeted Therapy - Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery
www.nature.com
September 10, 2025 at 12:00 PM
Nanobodies targeting lung cancer 🫁
Researchers at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) have developed a nanobody-based technology that identifies and attacks lung cancer cells, opening up new possibilities for cancer therapy.
Researchers at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) have developed a nanobody-based technology that identifies and attacks lung cancer cells, opening up new possibilities for cancer therapy.